Clinical Trial: Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07526493) titled 'Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.' on April 03.

Brief Summary: This study is an open-label, exploratory, prospective clinical trial with dose escalation(according to "3+3" design), to evaluate the safety and tolerability of QH103(Universal CD19 CAR-γδT Cell Injection)in the treatment of recurrent/refractory antibody-mediated neurological autoimmune diseases.

Study Start Date: April 01

Study Type: INTERVENTIONAL

Condition: Multiple Sclerosis (MS) Neuromyelitis Optica Spectrum Disorder (NMOSD) Auto...